Collaboration is in our genes
The Netherlands has an excellent reputation in the areas of immuno-oncology, neurology, infectious diseases, aging, regenerative medicine and stem cells. With a very well-documented population, the Netherlands offers high-quality infrastructure for pharmaceutical data and analysis. The regulatory process also offers a very clear cut and trustworthy path towards regulatory decisions.
On 20 November 2017, the General Affairs Council of the European Union decided that the European Medicines Agency (EMA) will relocate to Amsterdam when it leaves London in 2019. The Netherlands Medicines Evaluation Board (MEB) is a major contributor of expertise to the European network of pharmaceutical authorities coordinated by EMA. Amsterdam becoming the new home for EMA in Spring 2019, will strengthen the Dutch ecosystem for all human and veterinary medicines. It will also boost the Netherlands’ attractiveness to other companies and institutions in life sciences and health.
Major multinationals and innovative biotech companies like Janssen, Merck (MSD), Amgen, Sanofi, Genmab, Synthon, AstraZeneca, Kite Pharma, Aduro Biotech, Galapagos, AbbVie, Kiadis, Pharming, Merus and PRA Health Sciences, as well as state-of-the-art research institutes, make the Netherlands one of the most innovative countries in the world for BioPharmaceuticals.
The Netherlands: the Most Innovative Biopharmaceutical Community in Europe
A powerful team, ready to help
The Invest in Holland network is a collaborative team of the Netherlands Foreign Investment Agency (NFIA), regional economic development agencies and several large cities. The network works to provide a continuum of free, confidential support services to new foreign investors, as well as existing foreign investors that already have operations in the Netherlands.
World-Class Research & Education